[go: up one dir, main page]

IN2012DN03310A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03310A
IN2012DN03310A IN3310DEN2012A IN2012DN03310A IN 2012DN03310 A IN2012DN03310 A IN 2012DN03310A IN 3310DEN2012 A IN3310DEN2012 A IN 3310DEN2012A IN 2012DN03310 A IN2012DN03310 A IN 2012DN03310A
Authority
IN
India
Prior art keywords
moeties
peptiod
tetrapeptide
tripeptide
dipeptide
Prior art date
Application number
Inventor
Guido Franzoso
Albert Andrzej Jaxa-Chamiec
Caroline Minli Rachel Low
Simona Maria Monti
Menotti Ruvo
Laura Tornatore
Catherine Jane Tralau-Stewart
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Publication of IN2012DN03310A publication Critical patent/IN2012DN03310A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compounds based around tetrapeptide, tripeptide and dipeptide moeties and corresponding peptiod moeties. Related methods and pharmaceutical compositions for use in treatment of cancer, inflammatory diseases, and other disorders.
IN3310DEN2012 2009-10-22 2010-10-22 IN2012DN03310A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918579.4A GB0918579D0 (en) 2009-10-22 2009-10-22 Gadd45beta targeting agents
PCT/GB2010/001970 WO2011048390A2 (en) 2009-10-22 2010-10-22 Gadd45beta targeting agents

Publications (1)

Publication Number Publication Date
IN2012DN03310A true IN2012DN03310A (en) 2015-10-23

Family

ID=41426579

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3310DEN2012 IN2012DN03310A (en) 2009-10-22 2010-10-22

Country Status (14)

Country Link
US (2) US8993717B2 (en)
EP (2) EP3178836B1 (en)
JP (2) JP5961113B2 (en)
KR (1) KR20120099440A (en)
CN (1) CN102741269B (en)
AU (1) AU2010309594B2 (en)
BR (1) BR112012011332B1 (en)
CA (2) CA3034860A1 (en)
GB (1) GB0918579D0 (en)
IL (1) IL219325B (en)
IN (1) IN2012DN03310A (en)
MX (1) MX357801B (en)
RU (2) RU2577311C2 (en)
WO (1) WO2011048390A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
PL219569B1 (en) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cyclic tetrapeptides and their application
GB201107118D0 (en) * 2011-04-27 2011-06-08 Imp Innovations Ltd Method of diagnosis and prognosis
WO2013055051A1 (en) * 2011-10-14 2013-04-18 서울대학교산학협력단 Peptide nanostructure and a production method therefor
EP2771020B1 (en) * 2011-10-28 2017-07-12 NeoStrata Company, Inc. N-acyldipeptide derivatives and their uses
EP2827861A4 (en) * 2012-03-19 2016-03-16 Aposignal Bioscience Llc Composition and methods for cell modulation
CN104817616A (en) * 2014-01-30 2015-08-05 陈光健 Oligopeptide CD02, and preparation method and application thereof
CN104817618B (en) * 2014-01-30 2018-07-03 陈光健 Oligopeptides CD01 and its preparation method and application
GB201414542D0 (en) * 2014-08-15 2014-10-01 Imp Innovations Ltd Novel therapy
CN111574585B (en) * 2019-01-30 2021-10-01 浙江省医学科学院 A kind of cod skin oligopeptide and its separation and purification method and application
RU2716258C1 (en) * 2019-07-30 2020-03-11 Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий Peptide antagonist of the nmda receptor
KR102417496B1 (en) * 2019-11-29 2022-07-06 (주)수파드엘릭사 Peptide for inhibiting activity of androgen receptor and Cosmetic composition using the same
KR102348728B1 (en) * 2020-03-23 2022-01-12 주식회사 엘베이스 Pharmaceutical Composition for the Prevention or Treatment of Cancer
WO2021194228A1 (en) * 2020-03-23 2021-09-30 주식회사 엘베이스 Pharmaceutical composition for prevention or treatment of cancer
KR20230038457A (en) 2020-06-10 2023-03-20 알리고스 테라퓨틱스 인코포레이티드 Antiviral compounds for treating coronavirus, picornavirus and norovirus infections
WO2022203219A1 (en) * 2021-03-22 2022-09-29 주식회사 엘베이스 Pharmaceutical composition for prevention or treatment of cancer
US20230159587A1 (en) * 2021-03-22 2023-05-25 L-Base Co., Ltd. Pharmaceutical composition for preventing or treating cancer
JP2024525589A (en) 2021-07-09 2024-07-12 アリゴス セラピューティクス インコーポレイテッド Antiviral Compounds
IT202100023357A1 (en) * 2021-09-09 2023-03-09 Cheirontech S R L Peptides with anti-angiogenic activity
KR102786112B1 (en) * 2021-09-17 2025-03-27 주식회사 엘베이스 Pharmaceutical Composition for enhancing anticancer effects of anticancer drugs
US20250213645A1 (en) * 2021-09-17 2025-07-03 L-Base Co., Ltd. Pharmaceutical composition for modulating immune response
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
KR102494749B1 (en) * 2021-09-17 2023-02-06 주식회사 엘베이스 Method of characterizing responders to CAGE inhibitors for treatment of cancer
WO2023043261A1 (en) * 2021-09-17 2023-03-23 주식회사 엘베이스 Pharmaceutical composition for enhancing anticancer effect of anticancer drug
CN116350746B (en) * 2023-05-16 2024-03-22 海口桥水联合科技有限责任公司 Application of sardine peptide composition in medicine for treating allergic rhinitis
CN119874809A (en) * 2025-01-13 2025-04-25 广东工业大学 Antioxidant peptide and preparation method and application thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
HU187461B (en) 1981-10-22 1986-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing n-nitrozo-n-bracket-beta-chloroethyl-bracket closed-carbamoyl-peptides of citostatic activity
CA1257199A (en) 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
DE3813989A1 (en) * 1987-04-29 1988-11-10 Hoechst Ag Peptides with phospholipase A2-inhibiting action
IT1243390B (en) 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
FR2774674B1 (en) 1998-02-10 2000-03-24 Atochem Elf Sa PROCESS FOR THE PREPARATION OF AN AQUEOUS SOLUTION OF HYDROGEN PEROXIDE DIRECTLY FROM HYDROGEN AND OXYGEN AND DEVICE FOR IMPLEMENTING SAME
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
US20030162223A1 (en) 1999-10-22 2003-08-28 Lowery David E. Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CN1535264A (en) 2001-05-15 2004-10-06 ������ҩ��ʽ���� Arginine derivatives
NZ553507A (en) * 2001-07-13 2008-07-31 Cms Peptides Patent Holding Co Biologically active peptides
US7354898B2 (en) 2001-10-02 2008-04-08 University Of Chicago Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
WO2003028659A2 (en) 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
EP1573063A4 (en) 2002-08-19 2006-12-13 Yun Yen Treatment of liver deseases
CL2004000858A1 (en) 2003-04-22 2005-04-22 Avanir Pharmaceuticals PEPTIDES THAT INCLUDE AN ACID REGION, A LIPOFILICA OR AROMATICA AND A BASIC, WHICH PARTICIPATE IN INVERSE TRANSPORTATION OF COLESTEROL, PHARMACEUTICAL COMPOSITION CONTAINING THEM, USEFUL FOR THE TREATMENT OR PREVENTION OF HYPERCHOLESTEROLEMIA AND / OR ATEROSC
US7084111B2 (en) * 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
WO2006049597A1 (en) * 2004-10-27 2006-05-11 Avanir Pharmaceuticals Amino acid-derived compounds as modulators of the reverse cholesterol transport
PL1836159T3 (en) 2005-01-13 2013-09-30 Univ Wollongong Antibiotic binaphthyl derivatives
CN101155825B (en) * 2005-02-09 2014-11-26 赫里克斯生物医疗公司 Antimicrobial hexapeptides
WO2006105811A1 (en) * 2005-04-07 2006-10-12 Centre National De La Recherche Scientifique Compounds useful as modulators of the proteasome activity
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2007037297A1 (en) * 2005-09-29 2007-04-05 Maruha Corporation Composition effective for prevention and treatment of adult disease
JP2007217358A (en) * 2006-02-17 2007-08-30 Nippon Meat Packers Inc Anti-oxidizing peptide
WO2007117444A2 (en) * 2006-03-31 2007-10-18 Yinghe Hu Protein detection by aptamers
US20090312396A1 (en) 2006-07-10 2009-12-17 Astrazeneca Ab Methods for cancer treatment using tak1 inhibitors
WO2008021088A2 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
CN101153053B (en) * 2006-09-28 2012-02-01 中国医学科学院药物研究所 Bone-peptide, producing method, pharmaceutical composition and uses thereof
EP1964560A1 (en) 2007-02-28 2008-09-03 Helmholtz-Zentrum für Infektionsforschung GmbH Use of inhibitors of the degradation of p27 for the treatment of cancer
JP2011511076A (en) 2008-02-08 2011-04-07 エイルロン セラピューティクス，インコーポレイテッド Peptidomimetic macrocycles for therapeutic use
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
EP2390662A1 (en) 2010-05-27 2011-11-30 Erasmus University Medical Center Rotterdam Molecular classification of multiple myeloma

Also Published As

Publication number Publication date
JP2016166211A (en) 2016-09-15
JP5961113B2 (en) 2016-08-02
MX2012004755A (en) 2012-11-22
AU2010309594A1 (en) 2012-05-17
EP3178836A1 (en) 2017-06-14
RU2577311C2 (en) 2016-03-20
BR112012011332B1 (en) 2022-07-05
WO2011048390A2 (en) 2011-04-28
GB0918579D0 (en) 2009-12-09
CA3034860A1 (en) 2011-04-28
EP3178836B1 (en) 2019-12-25
RU2016102083A (en) 2018-11-20
CA2778236A1 (en) 2011-04-28
EP2491051A2 (en) 2012-08-29
MX357801B (en) 2018-07-25
AU2010309594B2 (en) 2016-01-07
WO2011048390A3 (en) 2011-11-03
KR20120099440A (en) 2012-09-10
RU2012120905A (en) 2013-11-27
US20120277164A1 (en) 2012-11-01
US8993717B2 (en) 2015-03-31
BR112012011332A2 (en) 2016-11-22
US9518083B2 (en) 2016-12-13
CN102741269A (en) 2012-10-17
JP2013508346A (en) 2013-03-07
IL219325B (en) 2019-02-28
IL219325A0 (en) 2012-06-28
US20150368294A1 (en) 2015-12-24
CN102741269B (en) 2017-08-29

Similar Documents

Publication Publication Date Title
IN2012DN03310A (en)
PH12014500053A1 (en) Proteasome inhibitors
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
PH12012500916B1 (en) Treatments for gastrointestinal disorders
EA201101522A1 (en) METHODS OF TREATMENT OF DISEASES WITH THE USE OF EPIMETABOLIC SWITCH (COENZIM Q10)
IN2012MN02591A (en)
MX2009006704A (en) New compounds.
MX366130B (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same.
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
EP4269563A3 (en) Anti-gd2 antibodies
MX2009006327A (en) Heterocycle compounds and methods of use thereof.
PL3208612T3 (en) Compositions and methods for the treatment of immune related diseases
EA201390803A1 (en) Bromodomain inhibitors and their use
PH12018500640A1 (en) Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi)
MX2011007930A (en) Crystalline insulin-conjugates.
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2011009033A (en) Tri-cyclic pyrazolopyridine kinase inhibitors.
ZA201004480B (en) Methods and compositions for oral administration of protein and peptide therapeutic agents
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
PH12012501389A1 (en) Hedgehog inhibitors
MX2010002667A (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors.
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
EP1993523A4 (en) Compositions and methods for treatment of disorders of protein aggregation
WO2014039074A3 (en) Therapeutic compositions and related methods